Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.85 |
| ▸ | CYSLTR1 | Q9Y271 | 10/20 | 0.66 |
| ▸ | CYSLTR2 | Q9NS75 | 5/20 | 0.62 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.61 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.60 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL421067 | 0.92 | GPBAR1 (1.00) | GPBAR1CYSLTR1CYSLTR2PDE10AFFAR1 | |
| SCHEMBL9581634 | 0.91 | GPBAR1 (0.97) | GPBAR1CYSLTR1CYSLTR2PDE10AFFAR1 | |
| SCHEMBL9581618 | 0.91 | GPBAR1 (0.97) | GPBAR1CYSLTR1CYSLTR2PDE10AFFAR1 | |
| SCHEMBL26632676 | 0.89 | GPBAR1 (0.92) | GPBAR1CYSLTR1CYSLTR2PDE10AFFAR1 | |
| SCHEMBL7457682 | 0.88 | GPBAR1 (0.90) | GPBAR1CYSLTR1CYSLTR2PDE10AFFAR1 | |
| SCHEMBL7718896 | 0.88 | GPBAR1 (0.90) | GPBAR1CYSLTR1CYSLTR2PDE10AFFAR1 | |
| SCHEMBL6932157 | 0.86 | FFAR1 (0.67) | GPBAR1CYSLTR1CYSLTR2FFAR1AKR1B1 | |
| SCHEMBL9033055 | 0.85 | GPBAR1 (0.85) | GPBAR1CYSLTR1CYSLTR2PDE10A | |
| SCHEMBL9033119 | 0.85 | GPBAR1 (0.85) | GPBAR1CYSLTR1CYSLTR2PDE10A | |
| SCHEMBL6932297 | 0.85 | GPBAR1 (0.65) | GPBAR1CYSLTR1CYSLTR2PDE10AFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1086079-B1 | DERIVATIVES OF HYDROXYPHENYLSULFANYLBENZOIC AND HYDROXYPHENYLSULFANYLARYLACETIC ACIDS | LECIVA A S (CZ) | 2003-05-07 | — | — | EP | claimed |
| US-6303612-B1 | USED AS ANTIINFLAMMATORY AND/OR ANTIASTHMATIC AGENTS | LECIVA, A.S. (CZ) | 2001-10-16 | — | — | US | claimed |
| EP-1086079-A1 | DERIVATIVES OF HYDROXYPHENYLSULFANYLBENZOIC AND HYDROXYPHENYLSULFANYLARYLACETIC ACIDS | Leciva, A.S. (CZ) | 2001-03-28 | — | — | EP | claimed |
| WO-1999067208-A1 | DERIVATIVES OF HYDROXYPHENYLSULFANYLBENZOIC AND HYDROXYPHENYLSULFANYLARYLACETIC ACIDS | LECIVA, A.S. (CZ) | 1999-12-29 | — | — | WO | claimed |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | MEDA AB (SE) | 2016-06-16 | — | — | US | disclosed |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | MEDA AB (SE) | 2016-06-16 | — | — | US | disclosed |
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | MEDA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | MEDA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | BIOLIPOX AB (SE) | 2008-04-03 | — | — | US | disclosed |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | BIOLIPOX AB (SE) | 2008-04-03 | — | — | US | disclosed |
| EP-1086079-B1 | DERIVATIVES OF HYDROXYPHENYLSULFANYLBENZOIC AND HYDROXYPHENYLSULFANYLARYLACETIC ACIDS | LECIVA A S (CZ) | 2003-05-07 | — | — | EP | disclosed |
| US-6303612-B1 | USED AS ANTIINFLAMMATORY AND/OR ANTIASTHMATIC AGENTS | LECIVA, A.S. (CZ) | 2001-10-16 | — | — | US | disclosed |
| EP-1086079-A1 | DERIVATIVES OF HYDROXYPHENYLSULFANYLBENZOIC AND HYDROXYPHENYLSULFANYLARYLACETIC ACIDS | Leciva, A.S. (CZ) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999067208-A1 | DERIVATIVES OF HYDROXYPHENYLSULFANYLBENZOIC AND HYDROXYPHENYLSULFANYLARYLACETIC ACIDS | LECIVA, A.S. (CZ) | 1999-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | LIPA, HRH2, HRH1 | GPBAR1 152/4885CYSLTR1 12/4885CYSLTR2 9/4885 |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | LIPA, HRH2, HRH1 | GPBAR1 152/4885CYSLTR1 12/4885CYSLTR2 9/4885 |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | LTB4R, LTA4H, LTA | GPBAR1 2453/4885CYSLTR1 59/4885CYSLTR2 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.